Phaseline

Companies › Braveheart Bio

Braveheart Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BHB-1893–Phase 3Cardiomyopathy, Hypertrophic ObstructiveOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07755904BHB-1893Phase 3Cardiomyopathy, Hypertrophic ObstructiveCardiovascularOct 2028

From the company's SEC filings

Cash of $123m on 2026-06-30; operating cash outflow about $45m a year; runway about 33 months at that burn, to Mar 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Inhibikase Therapeutics Grace Therapeutics Cytokinetics CeleCor Therapeutics MedTrace Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.